Akari Therapeutics Plc

AKTX · Nasdaq · SIC 2834: Pharmaceutical Preparations
295
SEC Filings

Business Summary

PART I . Overview We are an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. PH1s disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killi...

Next Earnings

Q2 FY2026 — expected 2026-09-24

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAKTXdiscussed_in_filing Cybersecurity
topic_mentionAKTXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001493152-26-013664EDGAR108K words
2025-04-152024-12-310000950170-25-054278EDGAR—
2024-03-292023-12-310000950170-24-038661EDGAR—
2016-03-232015-12-310001144204-16-089697EDGAR—
2015-02-112014-12-310001144204-15-007770EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001493152-25-022390EDGAR33K words
2025-08-132025-06-300001641172-25-023569EDGAR—
2025-05-142025-03-310000950170-25-071563EDGAR—
2024-11-192024-09-300000950170-24-128727EDGAR—
2024-08-192024-06-300000950170-24-098576EDGAR—
2024-05-152024-03-310000950170-24-060556EDGAR—
2016-05-122016-03-310001144204-16-101257EDGAR—
2015-11-232015-09-300001144204-15-067423EDGAR—
2015-08-122015-06-300001144204-15-048274EDGAR—
2015-05-122015-03-310001144204-15-029638EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-170001493152-26-010602EDGAR1K words
2026-03-020001493152-26-008570EDGAR—
2025-12-170001493152-25-028075EDGAR—
2025-12-160001493152-25-027969EDGAR—
2025-12-080001493152-25-026533EDGAR—
2025-11-260001493152-25-025177EDGAR—
2025-10-230001493152-25-019112EDGAR—
2025-10-160001493152-25-018269EDGAR—
2025-10-150001493152-25-018091EDGAR—
2025-09-290001493152-25-016039EDGAR—

295 total filings indexed. 270 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001541157
TickerAKTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedX0

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 6e9f12e082d785b06bfd60e3d90b6a100354535d58c064b4fe71e2ced565f88c
parent: b30f8b017c81a0bc36cdb6e78bafbbc5b06ebe9192d236a59fe1b9dba5b33045
content hash: 4dd1c456dc4d1113e72526f7f41471ff5ad2b364723438899a139667ad5af406
signed: 2026-04-13T04:43:34.332Z
sources: 15 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf